Corcept Therapeutics Incorporated (NASDAQ:CORT) traded up 7.1% on Thursday . The stock traded as high as $20.11 and last traded at $18.65. 1,051,317 shares were traded during mid-day trading, a decline of 24% from the average session volume of 1,384,940 shares. The stock had previously closed at $20.07.

Several equities research analysts recently weighed in on the stock. BidaskClub raised shares of Corcept Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, August 18th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Corcept Therapeutics in a report on Wednesday. Finally, Zacks Investment Research downgraded shares of Corcept Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $16.17.

The firm has a market cap of $2.13 billion, a PE ratio of 93.23 and a beta of 2.12. The company has a 50 day moving average of $17.82 and a 200 day moving average of $13.22.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings results on Tuesday, August 1st. The biotechnology company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.02. The business had revenue of $35.56 million for the quarter, compared to analysts’ expectations of $31.37 million. Corcept Therapeutics had a return on equity of 51.45% and a net margin of 22.28%. The firm’s quarterly revenue was up 80.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.01 earnings per share. On average, equities analysts anticipate that Corcept Therapeutics Incorporated will post $0.42 EPS for the current year.

In related news, Director David L. Mahoney sold 6,091 shares of the firm’s stock in a transaction dated Tuesday, July 18th. The stock was sold at an average price of $12.50, for a total value of $76,137.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David L. Mahoney sold 23,006 shares of the firm’s stock in a transaction dated Wednesday, July 19th. The shares were sold at an average price of $12.50, for a total value of $287,575.00. The disclosure for this sale can be found here. 19.20% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of CORT. Marshall Wace North America L.P. bought a new position in Corcept Therapeutics in the second quarter valued at about $13,942,000. Renaissance Technologies LLC boosted its holdings in Corcept Therapeutics by 44.4% in the second quarter. Renaissance Technologies LLC now owns 2,683,400 shares of the biotechnology company’s stock valued at $31,664,000 after acquiring an additional 824,900 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Corcept Therapeutics by 18.4% in the second quarter. Vanguard Group Inc. now owns 4,440,064 shares of the biotechnology company’s stock valued at $52,394,000 after acquiring an additional 689,554 shares during the last quarter. Teachers Advisors LLC boosted its holdings in Corcept Therapeutics by 316.9% in the second quarter. Teachers Advisors LLC now owns 817,245 shares of the biotechnology company’s stock valued at $9,643,000 after acquiring an additional 621,219 shares during the last quarter. Finally, Prudential Financial Inc. boosted its holdings in Corcept Therapeutics by 3,409.5% in the second quarter. Prudential Financial Inc. now owns 633,223 shares of the biotechnology company’s stock valued at $7,472,000 after acquiring an additional 615,180 shares during the last quarter. Institutional investors and hedge funds own 61.48% of the company’s stock.

WARNING: This report was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/10/12/corcept-therapeutics-incorporated-cort-trading-7-1-higher.html.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Receive News & Stock Ratings for Corcept Therapeutics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Incorporated and related stocks with our FREE daily email newsletter.